IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $265.000 thousand which beat the analyst consensus estimate of $258.000 thousand by 2.71 percent. This is a 38.74 percent increase over sales of $191.000 thousand the same period last year.